The global brachytherapy market size was valued at USD 996.40 million in 2025 and is projected to grow from USD 1,059.67 million in 2026 to USD 1,734.09 million by 2034, registering a CAGR of 6.35% during the forecast period (2026–2034). North America dominated the brachytherapy market with a market share of 43.97% in 2025.
Brachytherapy devices are medical systems used to deliver radiation directly to or near cancerous tissues using radioactive sources during or after treatment. These devices help target tumors precisely while limiting radiation exposure to surrounding tissues. They are widely used in prostate, cervical, breast, skin, and cancer treatments.
The brachytherapy devices market demand is increasing due to the prevalence of cancer, growing adoption of targeted radiation therapies, and preference for minimally invasive treatment approaches. Healthcare providers are adopting these systems to improve treatment precision and outcomes. Advances in radiation technology, increasing awareness of cancer treatment options, and expanding healthcare infrastructure are contributing to market growth.
Download a Free Sample To learn more about this report,
Shift from Conventional Applicators to Hybrid Intracavitary Interstitial Applicators
Brachytherapy centers are increasingly adopting hybrid applicators that combine intracavitary components with interstitial needles, particularly for locally advanced cervical cancers with parametrial or asymmetric tumor extension. These systems allow clinicians to customize needle positioning and dose distribution within a single implant. For example, Elekta’s Venezia applicator combines intracavitary treatment with interstitial needle placement, supporting more conformal dose delivery while helping limit exposure to nearby organs.
Growing Adoption of Electronic Brachytherapy
Another key market trend is the growing adoption of electronic brachytherapy systems that use miniature X-ray sources instead of conventional radioactive isotopes. Unlike traditional brachytherapy, electronic systems generate radiation electronically, eliminating the need to handle and store radioactive sources and simplifying certain radiation-safety requirements. For example, Xoft’s Axxent Electronic Brachytherapy System uses a miniature X-ray source to deliver localized radiation, supporting applications such as non-melanoma skin cancer treatment and enabling greater flexibility in outpatient treatment settings.
The brachytherapy market forecasts continued investment activity driven by the rising cancer treatment volumes and growing demand for precision radiation technologies. In July 2025, BrachyDOSE raised USD 639 thousand in seed funding led by Coinvest Capital, with participation from BSV Ventures and angel investor networks. The capital will support clinical testing, product development, and CE/MDR certification of its real-time radiation dose measurement technology for brachytherapy. The investment is intended to advance BrachyDOSE’s technology toward clinical adoption and commercialization.
The brachytherapy market has substantial exposure to supply chain disruptions due to its dependence on specialized radioactive sources, applicators, afterloaders, and precision components sourced from limited global suppliers. Disruptions in raw materials, radioactive isotope availability, manufacturing operations, transportation, and regulatory clearances are defining the market ecosystem by creating procurement challenges, extending equipment lead times, and increasing operational costs for healthcare providers worldwide. The market is experiencing an S-shaped recovery, characterized by an initial slowdown and accelerated recovery as manufacturers expand sourcing alternatives, improve inventory resilience, and restore production capacity.
Increasing Adoption of MRI-Guided Adaptive Brachytherapy and Growing Adoption of HDR Brachytherapy for Prostate Cancer Drive Market
The growing use of MRI-guided adaptive brachytherapy is driving demand for advanced brachytherapy systems by enabling clinicians to visualize residual tumors and surrounding organs more precisely during treatment. Unlike conventional image-guided approaches, MRI-based planning supports individualized dose adaptation according to tumor geometry and organ-at-risk position. The EMBRACE-II treatment framework has strengthened the role of MRI-guided adaptive brachytherapy by emphasizing precise dose targets while maintaining strict limits for bladder, rectum, sigmoid, and bowel exposure.
The increasing use of high-dose-rate brachytherapy in prostate cancer treatment is creating demand for advanced afterloaders, applicators, imaging systems, and treatment-planning software. HDR techniques allow radiation oncologists to deliver highly localized doses while adjusting treatment according to prostate anatomy and tumor characteristics. The availability of temporary radioactive-source placement also reduces the need for permanent implanted seeds in selected patients. This clinical flexibility is encouraging radiation oncology centers to expand HDR capabilities and invest in integrated image-guided brachytherapy infrastructure.
High Capital Costs of Applicators and Shortage of Specialized Radiation Oncology Personnel Restrain Market Expansion
Brachytherapy requires specialized equipment, including afterloaders, MRI-compatible applicators, treatment-planning software, and imaging infrastructure, which can create substantial upfront investment for healthcare facilities. MRI-guided brachytherapy is particularly capital intensive because treatment centers may require compatible imaging systems, applicators, and dedicated treatment workflows. These costs can limit adoption among smaller hospitals and radiation centers, especially in emerging markets where healthcare budgets remain constrained.
Brachytherapy procedures require coordinated expertise from radiation oncologists, medical physicists, radiation therapists, dosimetrists, and specialized nursing staff. Complex procedures involving interstitial implantation, image-guided planning, applicator placement, and real-time dose optimization require extensive training and workflow coordination. Limited availability of experienced personnel can reduce the number of procedures that centers are able to perform and increase treatment planning time.
Expansion of Brachytherapy for Recurrent Gynecological Cancers and Development of Patient-Specific Brachytherapy Applicators Offer Growth Opportunities to Market Players
The increasing use of salvage brachytherapy for locally recurrent gynecological cancers presents an opportunity for manufacturers to develop more adaptable applicators and advanced image-guided treatment systems. Reirradiation requires precise dose delivery because previously treated tissues have limited tolerance to additional radiation. Advanced interstitial and hybrid applicators can support customized implantation around recurrent lesions while reducing exposure to surrounding organs. This creates opportunities for manufacturers offering flexible applicator designs.
The development of patient-specific applicators using 3D printing is creating opportunities for manufacturers to address anatomical variations that conventional applicators cannot adequately accommodate. Customized devices are designed according to individual tumor location, surface geometry, and treatment requirements, potentially improving applicator positioning and dose conformity. This approach is particularly relevant for irregular skin, head-and-neck, and other anatomically challenging lesions. Manufacturers with capabilities in medical 3D printing, digital imaging, and treatment planning can leverage this opportunity to provide customized brachytherapy solutions.
Complex Radiation Safety Management and Patient Selection and Anatomical Variability Challenge Market Growth
Handling high-activity radioactive sources remains a significant challenge for facilities using conventional high-dose-rate brachytherapy. Treatment centers must maintain secure source storage, controlled access, radiation monitoring, emergency procedures, and regulatory compliance throughout the source lifecycle. Short-lived isotopes such as iridium-192 also require periodic source replacement, creating additional logistical and operational requirements.
Patient-specific anatomical differences can complicate applicator placement, dose distribution, and treatment reproducibility in brachytherapy procedures. Tumor location, organ movement, previous surgeries, and tissue changes may require customized implantation strategies and repeated imaging. These variations increase planning complexity and procedure time while making standardized treatment workflows more difficult.
The seeds segment accounted for a share of 42.87% in 2025 due to established prostate implantation protocols and sustained localized radiation delivery. Electronic brachytherapy systems grow through source-free operation and compact treatment configurations.
The electronic brachytherapy systems segment is expected to grow at a CAGR of 7.61% during the forecast period due to source-free radiation delivery and simplified radioactive material handling. Compact system designs, localized dose delivery, and suitability for outpatient superficial treatments support adoption among providers seeking flexible alternatives for selected non-melanoma skin cancer procedures.
Request Customizationto receive a tailored report.
The prostate cancer segment accounted for a share of 45.84% in 2025, led by its established clinical role of permanent seed implantation and high utilization of localized radiation. Patient selection pathways, mature treatment protocols, and outpatient implantation capabilities reinforce prostate brachytherapy demand across radiation oncology centers.
The skin cancer segment is expected to grow at a CAGR of 8.03% during the forecast period, driven by increasing use of superficial and electronic brachytherapy for localized lesions. Applicator flexibility, precise surface dose delivery, and reduced exposure to deeper tissues support adoption for selected non-melanoma skin cancers, particularly among dermatology practices.
The hospital segment accounted for a share of 60.02% in 2025 as they maintain radiation-shielded treatment rooms, multidisciplinary oncology teams, and advanced imaging infrastructure. Their ability to manage complex interstitial procedures, anesthesia requirements, and treatment planning further supports segment growth.
The ambulatory surgical center segment is expected to grow at a CAGR of 8.11% during the forecast period through streamlined outpatient workflows and focused procedural infrastructure. Shorter treatment pathways, efficient anesthesia services, and suitability for selected prostate implantation procedures support adoption where brachytherapy can be delivered without prolonged hospital stays or inpatient monitoring.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Advanced Image Guided Radiation Infrastructure and High Cancer Treatment Volumes
The North America brachytherapy market accounted for the largest regional share of 43.97% in 2025, driven by extensive adoption of image guided brachytherapy, advanced radiation oncology infrastructure, and high treatment volumes for prostate, cervical, and breast cancers. The region also benefits from established reimbursement systems, specialized radiation oncology teams, and a strong presence of leading brachytherapy manufacturers.
The US brachytherapy market was valued at USD 378.53 million in 2025, driven by increasing adoption of HDR brachytherapy, MRI-guided treatment, and advanced treatment-planning technologies. Healthcare providers are increasingly investing in precision radiation systems for prostate, cervical, skin, and breast cancers. The US National Cancer Institute estimates that approximately 2 million new cancer cases were expected in the US in 2025, supporting continued demand for targeted radiation treatment technologies.
The brachytherapy market in Canada was valued at USD 59.58 million in 2025, supported by expanding access to advanced radiation oncology services and increasing use of image-guided treatment approaches. Provincial cancer care networks are investing in modern radiation infrastructure to improve treatment precision and patient access. The country's established cancer treatment centers and growing adoption of HDR and image-guided brachytherapy support market development, particularly for prostate and gynecological cancers.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Expanding Cancer Care Infrastructure and Increasing Adoption of Image-Guided Brachytherapy
The Asia Pacific brachytherapy market is expected to grow at a CAGR of 8.58% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding oncology infrastructure, increasing cancer treatment volumes, and greater availability of advanced radiation therapy technologies across major healthcare systems. According to the World Health Organization, the Western Pacific region is experiencing a substantial cancer burden, increasing the need for accessible and precise radiation treatment technologies.
The China brachytherapy market was valued at USD 58.27 million in 2025, supported by increasing adoption of domestic radiation therapy equipment and localized medical technology manufacturing, which improves equipment availability and service responsiveness. Growing regional cancer-center networks outside major metropolitan areas are also expanding access to brachytherapy services. In addition, increasing use of prostate seed implantation and interstitial brachytherapy is broadening clinical applications, creating demand for specialized seeds, applicators, treatment-planning software, and radioactive-source technologies.
The India brachytherapy market was valued at USD 29.43 million in 2025, fueled by the use of high-dose-rate brachytherapy for recurrent and locally advanced cancers, where localized radiation can complement external beam treatment. Research from the Tata Memorial Centre evaluated abbreviated high-dose-rate brachytherapy for locally advanced cervical cancer following external-beam radiotherapy, supporting the use of HDR brachytherapy as a localized treatment approach. India’s Bhabha Atomic Research Centre (BARC) has developed the Karknidon-I HDR brachytherapy system, using a miniature Ir-192 source to deliver localized radiation for cancer treatment.
The Japan brachytherapy market was valued at USD 34.50 million in 2025, supported by established use of permanent seed implantation for localized prostate cancer, particularly within specialized urology and radiation oncology centers. The market also benefits from Japan’s regulated medical-device environment and structured reimbursement framework, which supports standardized access to approved brachytherapy procedures.
The brachytherapy market competitive landscape is moderately consolidated, with competition concentrated among established radiation oncology and medical technology companies. Leading players compete through advancements in HDR and LDR technologies, MRI-guided treatment, applicator design, and dose optimization capabilities. Emerging players are focusing on electronic brachytherapy, customized applicators, and specialized treatment solutions for underserved cancer indications. The brachytherapy market ecosystem is shaped by stringent radiation safety requirements, complex clinical workflows, and the need for integrated solutions that improve treatment accuracy while protecting surrounding healthy tissues.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Assisted Walking Devices Market Size, Share, Growth, 2034
Spirometer Market Size, Share, Growth, Analysis, Report, 2034
Vessel Sealing Devices Market Size, Share, Growth, Analysis, 2034
ECG Patch and Holter Monitor Market Size, Share, Growth, 2034
Tampon Market Size, Share, Growth, Opportunities, Analysis, 2034
Artificial Cornea and Corneal Implant Market Size, Share, 2034
We are featured on:
sales@straitsresearch.com